Dana Pizzuti - Jan 3, 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Med and Dev Officer
Signature
/s/ Marc Wilson
Stock symbol
CRNX
Transactions as of
Jan 3, 2024
Transactions value $
-$260,331
Form type
4
Date filed
1/4/2024, 04:45 PM
Previous filing
Dec 22, 2023
Next filing
Mar 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $243K +14.4K +243.19% $16.89 20.3K Jan 3, 2024 Direct
transaction CRNX Common Stock Sale -$503K -14.4K -70.86% $35.00 5.91K Jan 3, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Non-qualified stock option (Right to Buy) Options Exercise $0 -14.4K -6.52% $0.00 206K Jan 3, 2024 Common Stock 14.4K $16.89 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan.
F2 The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $35.00 per share. The range of sales prices on the transaction date was $34.82 to $35.32 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F3 The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.